German Cancer Research Center Selects Contur ELN from Accelrys
Accelrys, Inc. (MM) (NASDAQ:ACCL)
Historical Stock Chart
3 Years : From Apr 2012 to Apr 2015
SAN DIEGO, Dec. 5, 2012 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, is pleased to announce that the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) has licensed the server-based, on-premises version of the Contur Electronic Lab Notebook (ELN). The licensing agreement follows a successful two-month pilot program involving twenty chemists and biologists in four departments at DKFZ. When fully implemented, the Contur ELN will accelerate scientific innovation by improving collaboration, quality, efficiency and security for up to 1,000 researchers across the largest biomedical research institute in Germany.
"We wanted to deploy a single ELN across all scientific researchers to replace paper, facilitate information sharing and protect intellectual property," said Holger Haas, Head of the IT Department, DKFZ. "The single ELN system reduces cost of ownership while improving the management and reuse of information, as opposed to individual groups selecting and deploying different ELNs. Of all the ELNs we assessed, the Contur ELN was a clear leader because of its ease of use, its proven deployment track record and the excellent support we received from Accelrys during the pilot."
Along with increased competition for grants, academic researchers today face increasingly stringent data sharing and protection requirements, often imposed by funding organizations. Scientists also require a common research environment that supports distributed research teams and external partners while ensuring IP transparency, accountability and security.
"DKFZ's strategic decision reflects a growing trend in academic and research organizations today," said Mollie Hunter, Senior Vice President of Sales and Services at Accelrys. "In terms of rapid deployment, proven capabilities and bottom-line affordability, the Contur ELN is now well established as a valuable productivity tool for academic communities, offering proven performance for thousands of users. An ELN can pay for itself by preventing just one failed experiment or unnecessary repeated experiment."
Available as both a server-based, on-premises installation and as a software-as-a-service offering in the Cloud for Macs and PCs, the easy-to-deploy-and-use Contur ELN helps academic organizations meet the sophisticated requirements of today's research environment. In addition, the scalability of the Contur ELN accommodates the continually changing workflow and resourcing requirements encountered in academia.
For more information on deploying the Contur ELN in an academic environment, read the case study describing the adoption of a centralized ELN by three Swedish universities or view an on-demand webinar describing the Karolinska Institute's strategic approach to implementing a university-wide ELN. For more information on the Contur ELN, visit www.accelrys.com/products/eln/contur.
About the German Cancer Research Center
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 2,500 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg where promising approaches from cancer research are translated into the clinic. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. The center is a member of the Helmholtz Association of National Research Centers. Ninety percent of its funding comes from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Wurttemberg.
About Accelrys, Inc.
Accelrys (NASDAQ:ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.
Accelrys solutions are used by more than 1,300 companies in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, Calif., Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com.
SOURCE Accelrys, Inc.